Retinol
Berocca Pn, Infuvite, M.v.c. 9+, M.v.i, M.v.i. Lyophilized, Mvc, Vitamin A, Vitaped (retinol) is a small molecule pharmaceutical. Retinol was first approved as Aquasol a on 1982-01-01. It is known to target nuclear receptor subfamily 2 group C member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Aquasol a (discontinued: Afaxin, Alphalin, Aquasol a, Vi-dom-a, Vitamin a)
CombinationsInfuvite (discontinued: Berocca pn, M.v.c. 9+, M.v.i., M.v.i. lyophilized, Mvc, Vitaped)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Phytonadione
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a
+
Vitamin e
Vitamin a palmitate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AQUASOL A | Casper Pharma | N-006823 RX | 1982-01-01 | 1 products, RLD, RS |
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a palmitate
+
Vitamin e
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a
+
Vitamin e
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin
+
Thiamine hydrochloride
+
Vitamin a
+
Vitamin e
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pyridoxine
+
Riboflavin 5'-phosphate sodium
+
Thiamine
+
Vitamin a
+
Vitamin e
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pantothenic acid
+
Phytonadione
+
Pyridoxine
+
Riboflavin
+
Thiamine
+
Vitamin a palmitate
+
Vitamin e
Ascorbic acid
+
Biotin
+
Cholecalciferol
+
Cyanocobalamin
+
Dexpanthenol
+
Folic acid
+
Niacinamide
+
Pyridoxine
+
Riboflavin
+
Thiamine
+
Tocopherol acetate
+
Vitamin a
+
Vitamin k
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a
+
Vitamin e
+
Vitamin k
Alpha-tocopherol acetate
+
Ascorbic acid
+
Biotin
+
Cholecalciferol
+
Cyanocobalamin
+
Dexpanthenol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a palmitate
+
Vitamin k
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 5% retinol | C200263 | 2024-10-16 |
| acne relief retinol treatment and moisturizer | OTC monograph final | 2022-02-10 |
| acne wipeout clinical acne system | OTC monograph final | 2020-10-15 |
| advanced retinol moisturizer | C200263 | 2024-10-20 |
| advanced retinol rejuvenating eye cream | C200263 | 2024-11-07 |
| anyi beauty retinol brightening anti aging face cream | C200263 | 2024-04-29 |
| aoao retinol anti-aging box set | C200263 | 2025-01-08 |
| aoao retinol anti-aging eye cream | C200263 | 2024-11-06 |
| aoao retinol anti-aging milk | C200263 | 2024-11-07 |
| aoao retinol anti-aging neck cream | C200263 | 2024-11-07 |
Show 112 more
Indications
FDA
EMA
Show 26 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A11: Vitamins
— A11C: Vitamin a and d, incl. combinations of the two
— A11CA: Vitamin a, plain
— A11CA01: Retinol (vit a)
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AD: Retinoids for topical use in acne
— D10AD02: Retinol
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AX: Other nasal preparations in atc
— R01AX02: Retinol
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01X: Other ophthalmologicals in atc
— S01XA: Other ophthalmologicals in atc
— S01XA02: Retinol
HCPCS
No data
Clinical
Clinical Trials
4583 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | — | 1 | 2 | — | 3 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | 2 | — | 2 |
| Hepatitis c | D006526 | — | B19.2 | — | — | — | 1 | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | — | 1 | — | 1 |
| Hepatitis | D006505 | — | K75.9 | — | — | — | 1 | — | 1 |
| Chronic hepatitis | D006521 | — | K73.9 | — | — | — | 1 | — | 1 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | — | 1 | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | — | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | 1 | — | 1 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | — | 2 | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 1 | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | — | — | 1 | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | 1 | — | — | 1 |
| Respiratory tract diseases | D012140 | — | — | — | — | 1 | — | — | 1 |
| Germ cell and embryonal neoplasms | D009373 | — | — | — | — | 1 | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | — | — | 1 | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | 1 | — | — | 1 |
| Respiratory tract neoplasms | D012142 | EFO_0003853 | D14 | — | — | 1 | — | — | 1 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | — | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | 1 | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 1 | 1 |
| Fibrosis | D005355 | — | — | — | — | — | — | 1 | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | — | 1 | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 1 | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Retinol |
| INN | retinol |
| Description | Retinol is a retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified). It has a role as a human metabolite. It is a primary allylic alcohol and a retinoid. |
| Classification | Small molecule |
| Drug class | Vitamin |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1 |
Identifiers
| PDB | — |
| CAS-ID | 68-26-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL986 |
| ChEBI ID | 17336 |
| PubChem CID | 1071 |
| DrugBank | DB00162 |
| UNII ID | G2SH0XKK91 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NR2C2
NR2C2
Organism
Homo sapiens
Gene name
NR2C2
Gene synonyms
TAK1, TR4
NCBI Gene ID
Protein name
nuclear receptor subfamily 2 group C member 2
Protein synonyms
Nuclear hormone receptor TR4, Orphan nuclear receptor TAK1, Orphan nuclear receptor TR4, orphan receptor TR4, testicular nuclear receptor 4, Testicular receptor 4
Uniprot ID
Mouse ortholog
Nr2c2 (22026)
nuclear receptor subfamily 2 group C member 2 (P55093)
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Prenatal plus multivitamin plus dha minicaps
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,272 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use